NCT02902757

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Jonsson Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Detailed description

PRIMARY OBJECTIVES: I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT. II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and correlate them with objective response parameters such as Response Assessment in Neuro-Oncology (RANO) and survival. OUTLINE: Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
PROCEDURE	Computed Tomography	Undergo FDG PET/CT
RADIATION	Fludeoxyglucose F-18	Undergo FDG PET/CT
PROCEDURE	Positron Emission Tomography	Undergo FDG PET/CT

Timeline

• Start date: 2015-08-25
• Primary completion: 2025-01-29
• Completion: 2025-01-29
• First posted: 2016-09-16
• Last updated: 2025-12-17

Locations

1 site across 1 country: United States